Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00379847 · ClinicalTrials.gov registry record · Phase 3
An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia
A Phase 3 study of Hyponatremia, sponsored by Cumberland Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 251
- Enrollment target
- 20
- Study locations
NCT00379847: Completed Phase 3 study of Hyponatremia, sponsored by Cumberland Pharmaceuticals.
NCT00379847 is a Phase 3 study of Hyponatremia that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 251 participants, roughly in line with the 254-participant average among 3 other Hyponatremia trials with a reported enrollment target. The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00379847, a Phase 3 study of Hyponatremia, has completed, sponsored by Cumberland Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 251 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will investigate the application of a vasopressin antagonist in the treatment of hyponatremia most likely caused by inappropriate AVP secretion. The population studied will include patients with euvolemic or hypervolemic hyponatremia.
Conditions Studied
Interventions
- DRUG conivaptan
Study Locations (20)
Other
- - Afula
- - Ashkelon
- - Hadera
- 2 Sites - Haifa
- - Holon
- 2 Sites - Jerusalem
- - Nahariya
- - Rehovot
- 2 Sites - Safed
- - Tel Aviv
- - Ẕerifin
- - Amanzimototi
- - Bellville
Arizona
- - Tuscon
Colorado
- - Denver
District of Columbia
- - Washington D.C.
Georgia
- - Augusta
Michigan
- - Petoskey
Ohio
- - Cincinnati
South Carolina
- - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 251 participants |
| Start Date | 2004-02 |
| Est. Completion | 2005-06 |
| Phase | Phase 3 |
What the finished NCT00379847 record still lists
NCT00379847 is an interventional study that assigns participants to a tested intervention. The registered 251 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 254-participant average among 3 other Hyponatremia trials with a reported enrollment target.
The record links to 1 condition, with Hyponatremia appearing as the primary indexed condition, and to 1 intervention - of which conivaptan is the first listed.
NCT00379847 names 20 study sites across 8 states, led by Other, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT00379847 about?
NCT00379847 is a clinical study titled "An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia". This study will investigate the application of a vasopressin antagonist in the treatment of hyponatremia most likely caused by inappropriate AVP secretion. The population studied will include patients with euvolemic or hypervolemic hyponatremia.
What is the current status of trial NCT00379847?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 251 participants. The study started on 2004-02. Estimated completion is 2005-06.
What conditions does trial NCT00379847 study?
This clinical trial studies the following conditions: Hyponatremia.
What interventions are being tested in trial NCT00379847?
The interventions under investigation include: conivaptan (DRUG).
Who is sponsoring clinical trial NCT00379847?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00379847 being conducted?
This trial has 20 study locations across Arizona, Colorado, District of Columbia, Georgia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyponatremia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation
COMPLETED · Phase 3
-
Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia
COMPLETED · Phase 3
-
Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06043817 · 251 participants · Phase 1
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
- NCT02314988 · 252 participants · Phase 2
Tranexamic Acid to Reduce Blood Loss in Spine Surgery
- NCT03941756 · 252 participants · NA
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
- NCT05219617 · 252 participants · Phase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia